Carboplatin and programmed death‐ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model

Publisher： John Wiley & Sons Inc

E-ISSN： 1447-0756|44|2|303-311

ISSN： 1341-8076

Source： JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (ELECTRONIC), Vol.44, Iss.2, 2018-02, pp. : 303-311

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Programmed death‐ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy

By  

CANCER CYTOPATHOLOGY, Vol. 126, Iss. 2, 2018-02 ,pp. : 122-128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Paclitaxel in Cisplatin or Carboplatin-Pretreated Ovarian Cancer

By  

Oncology, Vol. 55, Iss. 3, 1998-04 ,pp. : 228-234

Karger

Access to resources Recommend Favorite

Clinical significance of programmed cell death‐ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 4, 2018-02 ,pp. : 822-832

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment

By  

Oncology, Vol. 87, Iss. 4, 2014-08 ,pp. : 232-245

Karger

Access to resources Recommend Favorite

A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome

By  

Oncology, Vol. 81, Iss. 5-6, 2012-01 ,pp. : 365-371

Karger

Access to resources Recommend Favorite